Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Minerva Ginecol ; 66(2): 155-64, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24848074

RESUMO

Endometriosis is a gynecological condition characterized by specific histological, molecular and clinical findings, that affects 5-10% of premenopausal women and has been implicated as a precursor for certain types of ovarian cancer. Clinical studies of endometriosis associated ovarian cancer (EAOC) suggest that patients present at a young age with a lower stage and grade of tumor, and are more likely to be premenopausal than women with other ovarian cancers. However, when overall survival is compared between these types of ovarian cancers, there is no difference noted. In addition, EAOC tumors are more likely to be found with a concurrent diagnosis of cancer, most commonly endometrial. Advances in technology, primarily the ability for whole genome sequencing, have led to the discovery of new mutations and further understanding of previously identified genes and pathways associated with EAOCs including PTEN, CTNNB1 (beta-catenin), KRAS, microsatellite instability and ARID1A. This paper will review the most recent clinical and molecular advances in the association of endometriosis and ovarian cancer.


Assuntos
Endometriose/complicações , Neoplasias Ovarianas/patologia , Pré-Menopausa , Fatores Etários , Endometriose/patologia , Feminino , Humanos , Instabilidade de Microssatélites , Mutação , Gradação de Tumores , Estadiamento de Neoplasias , Neoplasias Ovarianas/etiologia , Neoplasias Ovarianas/genética , Taxa de Sobrevida
2.
Diabetologia ; 51(7): 1169-80, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18491072

RESUMO

AIMS/HYPOTHESIS: Morphological changes that occur during pancreatic endocrine cell differentiation have been shown in rodent systems to be dependent on sequential alterations in transcription factor expression. However, similar data for humans have been limited. The aim of the present study was to provide a connection between pancreatic morphology, transcription factor gene expression and protein localisation during human fetal development. METHODS: Human fetal pancreases were examined at early (8-12 weeks of fetal age), middle (14-16 weeks) and late (19-21 weeks) stages, using immunohistological, microarray and qRT-PCR analyses. RESULTS: We observed a significant decrease in pancreatic duodenal homeobox 1 (PDX-1)(+)/cytokeratin 19(+) cells (p < 0.001), with a simultaneous increase in PDX-1(+)/insulin(+) cells from 8 to 21 weeks (p < 0.05). Increased PDX-1/insulin co-localisation within islet clusters was noted, while no co-expression of PDX-1 with glucagon was found, suggesting that loss of PDX-1 is essential for alpha cell formation. Given that neurogenin 3 (NGN3) expression is critical for establishing the endocrine cell programme in the rodent pancreas, we examined its expression pattern and co-localisation in PDX-1(+), insulin(+) and glucagon(+) cells. Co-localisation of NGN3 with PDX-1, insulin and glucagon was noted during early development, with significant decreases in middle and late stages (p < 0.001). Our microarray and co-localisation analyses of transcription factors linked to NGN3 demonstrated that ISL1 transcription factor (ISL1), neurogenic differentiation 1 (NEUROD1), NK2 related transcription factor related, locus 2 (NKX2-2) and paired box gene 6 (PAX6) were upregulated during development and present in all four endocrine cell types, while NK6 related transcription factor related, locus 1 (NKX6-1) was expressed exclusively in beta cells. CONCLUSIONS/INTERPRETATION: This study is an important step towards identifying key molecular factors involved in development of the human fetal endocrine pancreas.


Assuntos
Perfilação da Expressão Gênica , Regulação da Expressão Gênica no Desenvolvimento , Pâncreas/embriologia , Pâncreas/fisiologia , Fatores de Transcrição/genética , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Biomarcadores , Regulação para Baixo/genética , Idade Gestacional , Fator 1-alfa Nuclear de Hepatócito/genética , Fator 3-beta Nuclear de Hepatócito/genética , Fator 6 Nuclear de Hepatócito/genética , Proteína Homeobox Nkx-2.2 , Proteínas de Homeodomínio/genética , Humanos , Proteínas do Tecido Nervoso/genética , Proteínas Nucleares , Fatores de Transcrição Box Pareados/genética , Fatores de Transcrição da Família Snail , Transativadores/genética , Regulação para Cima/genética , Proteínas de Peixe-Zebra
3.
J Pediatr ; 138(5): 694-8, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11343045

RESUMO

OBJECTIVE: We tested the hypothesis that adding montelukast to budesonide would improve asthma control in children with inhaled glucocorticoid-dependent persistent asthma. STUDY DESIGN: In a multicenter, randomized, double-blind, crossover study, we compared the benefit of adding montelukast, 5 mg, or placebo once daily to budesonide, 200 microg, twice daily. RESULTS: After a 1-month run-in with budesonide, 200 microg, twice daily, 279 children were randomized to montelukast or placebo. The mean +/- SD age was 10.4 +/- 2.2 years, the mean forced expiratory volume in 1 second (FEV(1)) was 77.7% +/- 10.6% predicted, and reversibility was 18.1% +/- 12.9%. Compared with adding placebo to budesonide, adding montelukast produced significant improvements in mean percent change from baseline FEV(1) (P =.062 [P =.010 for per-protocol analysis]), mean absolute change from baseline FEV(1) (P =.040), mean increase from baseline in morning (P =.023) and evening (P =.012) peak expiratory flows, decrease in exacerbation days by approximately 23% (P <.001), decreased beta2-agonist use (P =.013), and reduced blood eosinophil counts (P <.001). The treatments did not differ significantly with regard to safety. CONCLUSIONS: Montelukast, 5 mg, added to budesonide improved asthma control significantly, indicated by a small additive effect on lung function and a clinically relevant decrease in asthma exacerbation days.


Assuntos
Acetatos/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Quinolinas/uso terapêutico , Acetatos/administração & dosagem , Acetatos/efeitos adversos , Antiasmáticos/administração & dosagem , Antiasmáticos/efeitos adversos , Asma/fisiopatologia , Budesonida/administração & dosagem , Budesonida/efeitos adversos , Budesonida/uso terapêutico , Ciclopropanos , Método Duplo-Cego , Quimioterapia Combinada , Volume Expiratório Forçado/fisiologia , Humanos , Valor Preditivo dos Testes , Qualidade de Vida , Quinolinas/administração & dosagem , Quinolinas/efeitos adversos , Sulfetos , Resultado do Tratamento
5.
Can Fam Physician ; 39: 793-8, 1993 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8495137

RESUMO

To evaluate the method used to assess and subsequently manage children with asthma, a retrospective chart review was carried out at the Children's Hospital of Western Ontario in London. Charts of 78 children diagnosed with asthma were randomly selected from emergency room daily records and inpatient files. Pharmacologic management of acute asthma proved adequate, but children with daily asthma symptoms likely would not have been identified or treated.


Assuntos
Asma , Doença Aguda , Albuterol/uso terapêutico , Asma/diagnóstico , Asma/terapia , Canadá , Criança , Pré-Escolar , Medicina de Emergência/métodos , Medicina de Emergência/estatística & dados numéricos , Serviço Hospitalar de Emergência/estatística & dados numéricos , Feminino , Hospitais Pediátricos , Humanos , Tempo de Internação/estatística & dados numéricos , Masculino , Auditoria Médica , Anamnese , Oxigenoterapia/estatística & dados numéricos , Admissão do Paciente/estatística & dados numéricos , Readmissão do Paciente/estatística & dados numéricos , Pediatria/métodos , Pediatria/estatística & dados numéricos , Exame Físico , Padrões de Prática Médica , Prednisona/uso terapêutico , Distribuição Aleatória , Recidiva , Estudos Retrospectivos
6.
J Appl Physiol (1985) ; 65(3): 1444-8, 1988 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-3182512

RESUMO

R. Peslin et al. measured thoracic gas volume (TGV) in adults using a new method employing low-frequency ambient pressure changes (APC) (J. Appl. Physiol. 62: 359-363, 1987). We extended that methodology and then tested the hypothesis that this technique was applicable to small mammals. TGV [at functional residual capacity (FRC)] by APC and by conventional Boyle's law was compared in 12 rabbits. The rabbits were anesthetized, tracheostomized, intubated, and placed in a pressure plethysmograph. Although in the method of Peslin et al. box pressure was oscillated at a single frequency, in our extension box pressure was oscillated simultaneously at two frequencies (0.1 and 0.2 Hz). Flow at the airway opening consisted of rapid events due to spontaneous breathing, superposed on slower events due to the alveolar gas compression. The slower events were analyzed to yield alveolar gas compliance and, by Boyle's law, FRC. FRC by APC was highly correlated to FRC by conventional plethysmography (r = 0.85). Compared with the methodology of Peslin et al., our extension relaxes a key limitation and yields systematically higher estimates of FRC. We conclude that this method is applicable to small mammals, despite an inherently more compliant chest wall, and that the methodological extension improves the estimate of FRC.


Assuntos
Medidas de Volume Pulmonar , Respiração Artificial , Animais , Capacidade Residual Funcional , Gases , Modelos Biológicos , Pressão , Coelhos , Tórax
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA